Loading
Naporafenib is an experimental small-molecule drug from Erasca in phase 3 trials for melanoma, with its target not yet stated publicly.
Naporafenib (ERAS-254, LXH254) is a small-molecule drug developed by Erasca. The sponsor describes its target as RAF (pan-RAF), which OnCo does not yet have a target page for. The sponsor states: An experimental pan-RAF inhibitor blocking RAF kinase signalling in the MAPK pathway, studied in combination with the MEK inhibitor trametinib in NRAS-mutant melanoma. ClinicalTrials.gov describes the intervention as: Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)), in melanoma. The largest, NCT06346067, plans to enrol 78 participants (actual) with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An experimental pan-RAF inhibitor blocking RAF kinase signalling in the MAPK pathway, studied in combination with the MEK inhibitor trametinib in NRAS-mutant melanoma.
1.Naporafenib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Naporafenib" OR ABSTRACT:"Naporafenib" OR TITLE:"ERAS-254" OR ABSTRACT:"ERAS-254" OR TITLE:"LXH254" OR ABSTRACT:"LXH254") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Naporafenib, not a curated reading list.
Shares NRAS, Mucosal melanoma, Melanoma and the tag pipeline.
Shares BRAF V600-mutant melanoma, Melanoma and the tag pipeline.
Shares NRAS and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.